Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$25.43+0.11 (+0.43%)
Close on Nov 16, 2026Market cap $827.89MP/E 20.5Yield –
Collegium Pharmaceutical revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Collegium Pharmaceutical's revenue for the twelve months ending Jun 30, 2026 was $808.21M, up 14.3% year over year. For fiscal 2025 it was $780.57M, up 23.6% from the year before. The highest annual figure on record is $780.57M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $780.57M | +23.6% |
| FY2024 | Dec 31, 2024 | $631.45M | +11.4% |
| FY2023 | Dec 31, 2023 | $566.77M | +22.2% |
| FY2022 | Dec 31, 2022 | $463.93M | +67.6% |
| FY2021 | Dec 31, 2021 | $276.87M | -10.7% |
| FY2020 | Dec 31, 2020 | $310.02M | +4.5% |
| FY2019 | Dec 31, 2019 | $296.70M | +5.8% |
| FY2018 | Dec 31, 2018 | $280.41M | +884.7% |
| FY2017 | Dec 31, 2017 | $28.48M | +1564.3% |
| FY2016 | Dec 31, 2016 | $1.71M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $199.88M | +6.3% |
| Q1 FY2026 | Mar 31, 2026 | $193.52M | +8.9% |
| Q4 FY2025 | Dec 31, 2025 | $205.45M | +12.9% |
| Q3 FY2025 | Sep 30, 2025 | $209.36M | +31.4% |
| Q2 FY2025 | Jun 30, 2025 | $188.00M | +29.4% |
| Q1 FY2025 | Mar 31, 2025 | $177.76M | +22.7% |
| Q4 FY2024 | Dec 31, 2024 | $181.95M | +21.5% |
| Q3 FY2024 | Sep 30, 2024 | $159.30M | +16.5% |
| Q2 FY2024 | Jun 30, 2024 | $145.28M | +7.2% |
| Q1 FY2024 | Mar 31, 2024 | $144.92M | +0.1% |
| Q4 FY2023 | Dec 31, 2023 | $149.75M | +15.5% |
| Q3 FY2023 | Sep 30, 2023 | $136.71M | +7.6% |
| Q2 FY2023 | Jun 30, 2023 | $135.55M | +9.7% |
| Q1 FY2023 | Mar 31, 2023 | $144.77M | +72.9% |
| Q4 FY2022 | Dec 31, 2022 | $129.62M | +373.7% |
| Q3 FY2022 | Sep 30, 2022 | $127.01M | +61.1% |
| Q2 FY2022 | Jun 30, 2022 | $123.55M | +49.0% |
| Q1 FY2022 | Mar 31, 2022 | $83.75M | -4.5% |
| Q4 FY2021 | Dec 31, 2021 | $27.36M | -64.1% |
| Q3 FY2021 | Sep 30, 2021 | $78.84M | -0.4% |
| Q2 FY2021 | Jun 30, 2021 | $82.94M | +6.3% |
| Q1 FY2021 | Mar 31, 2021 | $87.72M | +14.7% |
| Q4 FY2020 | Dec 31, 2020 | $76.27M | +2.8% |
| Q3 FY2020 | Sep 30, 2020 | $79.18M | +8.5% |
| Q2 FY2020 | Jun 30, 2020 | $78.06M | +4.0% |
| Q1 FY2020 | Mar 31, 2020 | $76.51M | +2.7% |
| Q4 FY2019 | Dec 31, 2019 | $74.20M | +1.1% |
| Q3 FY2019 | Sep 30, 2019 | $72.94M | +3.9% |
| Q2 FY2019 | Jun 30, 2019 | $75.04M | +2.7% |
| Q1 FY2019 | Mar 31, 2019 | $74.52M | +16.9% |
| Q4 FY2018 | Dec 31, 2018 | $73.43M | +580.3% |
| Q3 FY2018 | Sep 30, 2018 | $70.18M | +487.2% |
| Q2 FY2018 | Jun 30, 2018 | $73.06M | +1952.3% |
| Q1 FY2018 | Mar 31, 2018 | $63.75M | +2835.0% |
| Q4 FY2017 | Dec 31, 2017 | $10.79M | +728.4% |
| Q3 FY2017 | Sep 30, 2017 | $11.95M | +2828.9% |
| Q2 FY2017 | Jun 30, 2017 | $3.56M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.30M | – |
| Q3 FY2016 | Sep 30, 2016 | $408.00K | – |
See a number that looks wrong?